Fig 1.
ROP, retinopathy of prematurity; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Table 1.
Baseline characteristics of the two groups after 1:1 matching for body weight at treatment within 100 g.
Fig 2.
A, Mean BWs from 7 days before treatment to 14 days after treatment. B, Weekly BW gains for the 7 days before treatment (pre-treatment week), the 7 days after treatment (first post-treatment week), and the period from 7 to 14 days after treatment (second post-treatment week). BW gain in the IVB group during the first post-treatment week was significantly lower than that in the PC group. BW, body weight; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Fig 3.
Effect of Pre-treatment BW on BW gain post-treatment.
The BW gains during the first post-treatment week in infants with BW <1500 g at treatment and infants with BW ≥1500 g are shown. The BW gain in infants with BW <1500 g at treatment was significantly smaller than that in infants with BW ≥1500 g at treatment in the IVB group, but not in the PC group. BW, body weight; IVB, intravitreal injection of bevacizumab; PC, photocoagulation.
Fig 4.
Parameters other than BW gain.
A–F, Changes in systolic (A) and diastolic (B) blood pressure, pulse rate (C), oxygen concentration set on the ventilator (D), volume of milk sucked (E), and urine output (F) from 7 days before treatment to 14 days after treatment.